The Journal of invasive cardiology · 2001
Initial experience with a newer generation coronary stent.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Manolis A S, Chiladakis J, Hahalis G, Agelopoulos G
Аннотация
BACKGROUND: Recently, several newer generation stents have become available promising to improve upon the results of coronary angioplasty (PTCA) with its attendant acute and chronic complications. The aim of this study was to prospectively review the results of a preliminary experience with the newer generation R stent in a series of 56 patients.
METHODS: This study included 47 men and 9 women, aged 57 +/- 10 years, who presented with stable angina and/or positive exercise testing (n = 12), unstable angina (n = 42), or acute myocardial infarction (n = 2). A consistent approach by a single operator for implantation of the R stent (Orbus Inc., The Netherlands) included stent oversizing (by 0.5 mm) and high pressure (> 12--16 bar) deployment. Dilated vessels comprised the left anterior descending (n = 37) including the diagonal branch in 2 patients, the right coronary artery (n = 17), the left circumflex (n = 13), or a saphenous vein graft (n = 1). The mean left ventricular ejection fraction was 52 +/- 8% and the initial coronary artery stenosis was 85 +/- 8%. Stents were implanted for dissection and/or suboptimal PTCA result or electively.
RESULTS: The procedure was successful in all 56 patients (100%). The residual stenosis was < 0--10%. Direct stenting without balloon predilation was performed in 21 patients. Single stents were used in 36 patients and > or = 2 stents in 20 patients. Abciximab (n = 22), eptifibatide (n = 8) or tirofiban (n = 1) was administered in 31 patients (55%). A stent-related complication was noted in one patient (stent misplacement). All patients were discharged alive without infarct or need for surgery. There were no events of subacute stent thrombosis; all patients received combined therapy with aspirin and clopidogrel, the latter for 1 month. In one patient who had received abciximab, severe thrombocytopenia (0 platelet count) was detected at 3 days after discharge but it was fully reversible with no sequelae. Over 5.2 +/- 2.8 (range, 1--11) months, there was one sudden death and two clinical restenoses; no other late complication occurred.
CONCLUSION: Initial experience with 73 R stents in 56 patients and a consistent approach by a single operator of stent oversizing and high-pressure deployment resulted in high procedural success (100%), lack of stent thrombosis (0%), and a low stent-related complication rate (1.8%), while the design and profile of the R stent allowed for direct stenting in 37.5% of patients. One should be vigilant for the sporadic occurrence of severe thrombocytopenia with use of IIb/IIIa inhibitors.
METHODS: This study included 47 men and 9 women, aged 57 +/- 10 years, who presented with stable angina and/or positive exercise testing (n = 12), unstable angina (n = 42), or acute myocardial infarction (n = 2). A consistent approach by a single operator for implantation of the R stent (Orbus Inc., The Netherlands) included stent oversizing (by 0.5 mm) and high pressure (> 12--16 bar) deployment. Dilated vessels comprised the left anterior descending (n = 37) including the diagonal branch in 2 patients, the right coronary artery (n = 17), the left circumflex (n = 13), or a saphenous vein graft (n = 1). The mean left ventricular ejection fraction was 52 +/- 8% and the initial coronary artery stenosis was 85 +/- 8%. Stents were implanted for dissection and/or suboptimal PTCA result or electively.
RESULTS: The procedure was successful in all 56 patients (100%). The residual stenosis was < 0--10%. Direct stenting without balloon predilation was performed in 21 patients. Single stents were used in 36 patients and > or = 2 stents in 20 patients. Abciximab (n = 22), eptifibatide (n = 8) or tirofiban (n = 1) was administered in 31 patients (55%). A stent-related complication was noted in one patient (stent misplacement). All patients were discharged alive without infarct or need for surgery. There were no events of subacute stent thrombosis; all patients received combined therapy with aspirin and clopidogrel, the latter for 1 month. In one patient who had received abciximab, severe thrombocytopenia (0 platelet count) was detected at 3 days after discharge but it was fully reversible with no sequelae. Over 5.2 +/- 2.8 (range, 1--11) months, there was one sudden death and two clinical restenoses; no other late complication occurred.
CONCLUSION: Initial experience with 73 R stents in 56 patients and a consistent approach by a single operator of stent oversizing and high-pressure deployment resulted in high procedural success (100%), lack of stent thrombosis (0%), and a low stent-related complication rate (1.8%), while the design and profile of the R stent allowed for direct stenting in 37.5% of patients. One should be vigilant for the sporadic occurrence of severe thrombocytopenia with use of IIb/IIIa inhibitors.